FIG. 1.

Ad-ISF35 intratumoral direct injection (IDI) results in tumor regression by inducing local and systemic immune responses. (A) A20 tumor-bearing mice received three weekly IDI of the vehicle, Ad5 (3×10¹⁰ vp), or Ad-ISF35 (3×10¹⁰ vp) as shown by the arrows. Tumor size was measured over time and statistical analysis was performed. (B) Survival curve of mice receiving the vehicle, Ad5, and Ad-ISF35. (C) Tumor growth of bilateral injection of A20 cells. The tumor present on the right flank was injected with Ad-ISF35 or the vehicle (control). The tumor on the left was not injected. (D) Percentage of tumor-free mice on the right flank (Ad-ISF35 injected) and left flank (noninjected). (E) Survival curve of mice rechallenged with A20 cells 3 months after Ad-ISF35 IDI-induced tumor regression. Age-matched control group previously untreated was also injected with the same batch of A20 cells. Error bars indicate the standard deviation.